Protagonist Therapeutics Reports Promising Data for Icotrokinra in Ulcerative Colitis

Protagonist Therapeutics has announced positive results from its Phase 2b ANTHEM-UC study of icotrokinra in adults with moderate to severe ulcerative colitis. The study achieved its primary endpoint of clinical response at all doses, with a significant 36.5% of patients showing endoscopic improvement. At the highest dose, 30.2% reached clinical remission by Week 12.

The findings highlight icotrokinra's potential as a first-in-class oral peptide targeting the IL-23 receptor, offering new hope for patients. The promising data paves the way for a Phase 3 trial in ulcerative colitis expected to commence in late 2025.

Patients on the 400 mg dose showed a 63.5% clinical response rate compared to 27% on placebo. The safety profile was comparable across all groups, suggesting a favorable balance of efficacy and safety.